R G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, et al: Future perspectives in melanoma research Meeting report in the “Melanoma Bridge Napoli, December 2nd-4th 2012”. J Transl Med 2013, 11:137. 29. L V, Ecsedi S, Sz losi AG, T h R, V keleti L, R osy Z, B y A, Ad y R, Bal s M: Characterization of candidate gene copy quantity alterations in the 11q13 area in addition to BRAF and NRAS mutations in human melanoma. Mod Pathol 2009, 22:1367?378. 30. Carlino MS, Gowrishankar K, Saunders CA, Pupo GM, Snoyman S, Zhang XD, Saw R, Becker TM, Kefford RF, Extended GV, Rizos H: Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol Cancer Ther 2013, 12:1332?342. 31. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F 3rd, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL: KIT gene mutations and copy quantity in melanoma subtypes. Clin Cancer Res 2008, 14:6821?828. 32. Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lu A, Guo J: Large-scale evaluation of KIT aberrations in Chinese individuals with melanoma. Clin Cancer Res 2011, 17:1684?691. 33. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O’Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE: Imatinib for melanomas harboring mutationally activated orColombino et al. Journal of Translational Medicine 2014, 12:117 http://translational-medicine/content/12/1/Page eight of34.n-Octyl β-D-glucopyranoside Chemscene 35.36. 37. 38. 39.40.41.42.43.44.45.46.amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013, 31:3182?190. Johnson TM, Hamilton T, Lowe L: Multiple primary melanomas. J Am Acad Dermatol 1998, 39:422?27. Carli P, De Giorgi V, Chiarugi A, Stante M, Giannotti B: Numerous synchronous cutaneous melanomas: implications for prevention. Int J Dermatol 2002, 41:583?85. Haluska FG, Hodi FS: Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998, 16:670?82. Miller AJ, Mihm MC: Melanoma. N Engl J Med 2006, 355:51?five. Thompson JF, Scolyer RA, Kefford RF: Cutaneous melanoma in the era of molecular profiling. Lancet 2009, 374:362?65. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty KT, Wargo JA, Garraway LA: MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.3-(4-Fluorophenoxy)azetidine Chemscene Cancer Discov 2014, 4:61?eight.PMID:24605203 Colombino M, Lissia A, Capone M, De Giorgi V, Massi D, Stanganelli I, Fonsatti E, Maio M, Botti G, Carac?C, Mozzillo N, Ascierto PA, Cossu A, Palmieri G: Heterogeneous distribution of BRAF/NRAS mutations amongst Italian sufferers with advanced melanoma. J Transl Med 2013, 11:202. Lee JH, Choi JW, Kim YS: Frequencies of BRAF and NRAS mutations are diverse in histological varieties and internet sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011, 164:776?84. Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel D, Herlyn M, Bastian BC: Cyclin D1 is really a c.
